SOLVE FSHD invests US$10 Million in Vita Therapeutics

VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) — SOLVE FSHD, a venture-philanthropic group catalyzing the tempo of innovation to speed up a treatment for facioscapulohumeral muscular dystrophy (FSHD), introduced right now an funding of US$10M million in Vita Therapeutics; a cell engineering firm harnessing the facility of genetics to develop novel mobile therapies to deal with muscular dystrophies and stable tumours.

Chip Wilson, founding father of lululemon athletica and SOLVE FSHD stated, “Living with FSHD for over 30 years, my upper body muscles are quite wasted. We are hopeful that the Vita cell therapy approach will stimulate muscle regeneration and will help people like me to build up muscle faster than it breaks down.”

The funding is a part of a $31M Series B financing spherical led by Cambrian Biopharma. In addition to Solve FSHD becoming a member of, different new buyers included Riptide Ventures and Cedars Sinai, which participated alongside TEDCO and different present buyers. Proceeds from the financing can be used to advance Vita’s lead pre-clinical program VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to the clinic. It can even fund the event of Vita’s latest program, VTA-120, for the remedy of sufferers with FSHD and to additional increase Vita’s discovery pipeline. Since inception, Vita has raised a complete of $66 million.

“Currently there are no treatments available for FSHD, and there is an urgent need to develop disease-modifying treatments that not only regenerate muscle but also correct the genetic defect that otherwise leads to the muscle’s inability to repair itself,” stated Eva Chin, Executive Director for SOLVE FSHD. “We are pleased to support Vita as they continue to expand their induced pluripotent stem cell (iPSC) technology towards FSHD while further progressing their treatment for LGMD.”

About SOLVE FSHD
SOLVE FSHD is funding revolutionary biotech and biopharma analysis and growth actions that speed up novel remedies for Facioscapulohumeral muscular dystrophy (FSHD). It is absolutely funded and created by Canadian entrepreneur and philanthropist Chip Wilson. The founding father of yoga-inspired athletic attire firm lululemon athletica inc. has been residing with FSHD for the final three many years of his life. He has dedicated $100 million of his personal cash to create SOLVE FSHD and kick-start funding into initiatives that match the group’s mission: speed up analysis into new therapies and discover a treatment for the dysfunction by 2027. https://solvefshd.com/ 

For early-stage corporations, contact Solve FSHD at [email protected].

If you may have FSHD and wish to discover out about scientific trials or be included in the FSHD registry, please see Solve FSHD’s web site – https://solvefshd.com/

About Vita Therapeutics
Vita Therapeutics is a biotechnology firm creating state-of-the-art mobile therapeutics for the remedy of debilitating neuromuscular ailments and cancers. Vita Therapeutics makes use of induced pluripotent stem cell (iPSC) expertise to engineer particular cell sorts designed to interchange these which might be

faulty in sufferers. The Company is progressing its lead program VTA-100 for the remedy of limb-girdle muscular dystrophy (LGMD2A) with the purpose of submitting an Investigational New Drug Application with the US Food and Drug Administration in the following 18 months. Long time period, the Company is creating its pipeline of mobile therapies following a twin growth technique starting with autologous-derived cells earlier than transferring to a common hypoimmunogenic cell line. Vita Therapeutics is at the moment working with quite a few companions, together with PanCella, Wyss Institute, and Johns Hopkins University, to advance their scientific applications. Learn extra concerning the firm at www.Vitatx.com

Media inquiries, please contact:
Carla Bosacki, Account Director
PR Associates
[email protected]
T: 416-522-9677